A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have a slightly lower risk of developing diabetic foot problems compared to those taking glucagon-like peptide-1 (GLP-1) receptor agonists.
from Medical Xpress - latest medical and health news stories https://ift.tt/7GYeVhL
